Aquestive Therapeutics (AQST) executive compensation, 2026 proxy

Daniel Barber, President and Chief Executive Officer, was paid $3.5M in 2025, down 16% from $4.2M the year before.

Filed
April 24, 2026
Annual meeting
June 10, 2026
Pay year
2025
Named executives
3
CEO total pay
$3.5M-16% vs prior year
CEO pay in equity
69%$2.4M in awards
CEO Stock Awards
$1,547,342For 2025
CEO Option Awards
$877,200For 2025
CEO Non-Equity Incentive
$409,132Annual incentive for 2025

How Barber was paid

$3.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary19%Stock awards44%Option awards25%Non-equity incentive12%

Named executive officers

ExecutiveTotal
Daniel BarberPresident and Chief Executive Officer$3,493,559
Lori J. BraenderCorporate Secretary, Former Chief Legal Officer and Chief Compliance Officer$1,348,238
A. Ernest Toth, Jr.Chief Financial Officer$1,323,547

What changed and why

  • $3.5MDaniel Barber received a total compensation of $3,493,559 in fiscal year 2025, reflecting a decrease from the prior year total of $4,181,472.
  • Lori J. Braender ceased serving as Chief Legal Officer and Chief Compliance Officer effective April 2, 2026.
  • $1.3MA. Ernest Toth, Jr. was newly included as a named executive officer for 2025 with a total compensation of $1,323,547.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.